PO08 | NEXT-GENERATION THROMBOLYTICS: ENGINEERING STREPTOKINASE FOR ENHANCED ACTIVITY AND REDUCED IMMUNOGENICITY
M. Kanwal1|2 | 1Consiglio Nazionale delle Ricerche, Naples, Italy; 2Department of Environmental, Biological and Chemical Sciences and Technologies, University of Campania "Luigi Vanvitelli", Italy
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Authors
Introduction. Streptokinase (SK) is a widely used thrombolytic agent, but its clinical utility is limited due to its high immunogenicity, which results in rapid inactivation by antibodies. This study aimed to engineer a truncated variant of streptokinase to reduce its immunogenicity while maintaining its fibrinolytic activity.
Aim. The primary objective was to reduce the immunogenicity of streptokinase through selective truncation of its C-terminal antigenic segment and to assess whether this modification could preserve its fibrinolytic activity.
Materials and Methods. A PCR-based truncation strategy was used to remove a C-terminal segment (residues 353–414) of streptokinase. The truncated gene was subcloned into a bacterial expression vector and expressed in Escherichia coli. The protein was purified, and its fibrinolytic activity was evaluated using plasminogen activation and fibrin clot-dissolution assays. Antibody binding was assessed using human sera to measure the reduction in immunogenicity.
Results. The truncated streptokinase variant exhibited a significant reduction in antibody binding, indicating a decrease in immunogenic epitopes associated with the C-terminal region. Despite the truncation, the engineered variant retained robust plasminogen activation activity and effectively dissolved fibrin clots, comparable to the native streptokinase.
Conclusions. C-terminal truncation of streptokinase represents a promising strategy for reducing immunogenicity without compromising therapeutic efficacy. This engineered variant could offer a safer, more effective alternative for thrombolytic therapy, with reduced immunogenic responses and retained fibrinolytic activity, making it a potential candidate for clinical use.
Downloads
Citations
How to Cite
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Most read articles by the same author(s)
- Società Italiana di Emostasi e Trombosi, PO27 | URINE QUALITATIVE ASSESSMENT OF DIRECT ORAL ANTICOAGULANTS IN ROUTINE CLINICAL PRACTICE , Bleeding, Thrombosis and Vascular Biology: Vol. 5 No. s1 (2026)
- Società Italiana di Emostasi e Trombosi, PO11 | THROMBOEMBOLIC EVENTS DURING PERIOPERATIVE THERAPY FOR RESECTABLE AND BORDERLINE RESECTABLE PANCREATIC CANCER IN THE PREOPANC-2 TRIAL , Bleeding, Thrombosis and Vascular Biology: Vol. 5 No. s1 (2026)
- Società Italiana di Emostasi e Trombosi, PO13 | OUTPATIENT TREATMENT OF VENOUS THROMBOEMBOLISM AND SUBSEQUENT RISK OF CANCER , Bleeding, Thrombosis and Vascular Biology: Vol. 5 No. s1 (2026)
